ReviewGynecologic oncology2018
Aspirin use and endometrial cancer risk and survival.
Review in Gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Prophylactic and therapeutic effects of aspirin in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Biochemical and haemostatic variables associated with metastasis in dogs with carcinoma or sarcoma.The Journal of small animal practice · 2026Article
- Non-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study.International journal of cancer · 2025Article
- Inflammation in cancer: therapeutic opportunities from new insights.Molecular cancer · 2025Review
- Sulindac exhibits anti-proliferative and anti-invasive effects in uterine serous carcinoma cells.Journal of cancer research and clinical oncology · 2024Article
- The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review.Cancer reports (Hoboken, N.J.) · 2024Review
- Who is Focusing on Women's Health: A Bibliometric Analysis of Global Research Trends on Overweight in Female Patients with Gynecologic or Breast Cancer.International journal of women's health · 2024Article
- The Effect of Acetylsalicylic Acid, as a Representative Non-Steroidal Anti-Inflammatory Drug, on the Activity of Myeloperoxidase.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Acetylsalicylic Acid-Primus Inter Pares in Pharmacology.Molecules (Basel, Switzerland) · 2022Review
- New Organoselenium (NSAIDs-Selenourea and Isoselenocyanate) Derivatives as Potential Antiproliferative Agents: Synthesis, Biological Evaluation and in Silico Calculations.Molecules (Basel, Switzerland) · 2022Article
- Article
- Effects of Anesthesia and Anesthetic Techniques on Metastasis of Lung Cancers: A Narrative Review.Cancer management and research · 2022Review
- Postoperative Systemic Immune-Inflammation Index (SII): A Superior Prognostic Factor of Endometrial Cancer.Frontiers in surgery · 2021Article
- Aspirin inhibits tumor progression and enhances cisplatin sensitivity in epithelial ovarian cancer.PeerJ · 2021Article
- Aspirin associated with a decreased incidence of uterine cancer: A retrospective population-based cohort study.Medicine · 2020Observational
- Article
- Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer.Gynecologic oncology · 2019Article
- Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.Archives of gynecology and obstetrics · 2019Article
- NLRP3 inflammasome activation by estrogen promotes the progression of human endometrial cancer.OncoTargets and therapy · 2019Article
- High prevalence of metabolic syndrome in women newly diagnosed with endometrial cancer.Gynecologic oncology reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The role of acetylsalicylic acid (aspirin) as a chemo-preventive and adjuvant therapeutic agent for cancers is generating attention. Mounting evidence indicates that aspirin reduces the incidence and mortality of certain obesity-related cancers, particularly colorectal cancer. In endometrial cancer, previous studies examining the effect of aspirin remain inconsistent as to the reduction in the risk of endometrial cancer. While some evidence indicates protective effects in obese women, other studies have showed a potential deleterious effect of these medications on endometrial cancer outcomes. However, exposure measurement across studies has been inconsistent in recording dose, duration, and frequency of use; thus making comparisons difficult. In this article, we review the evidence for the association between endometrial cancer and obesity, the pharmacological differences between regular- and low-dose aspirin, as well as the potential anti-tumor mechanism of aspirin, supporting a possible therapeutic effect on endometrial cancer. A proposed mechanism behind decreased cancer mortality in endometrial cancer may be a result of inhibition of metastasis via platelet inactivation and possible prostaglandin E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.